HCW Biologics Inc.
HCWBHealthcareNASDAQBiotechnology · Last scanned Jul 22, 2026
Scan Results
Daily timeframeHCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. With a market capitalization of $5.4M, it sits in micro-cap territory. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases.
Market Cap
$5.4M
Beta
2.30
P/E (TTM)
—
P/E (Fwd)
-6.15
EPS (TTM)
$-44.01
EPS (Fwd)
$-0.55
ROE
—
ROA
-15.1%
Cash
$1.2M
Total Debt
$6.6M
Free CF
-$10.4M
52W Change
-87.0%
Annual Financials
Cash vs Debt
Where HCWB stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, HCWB finished 23.73% below its 150-day moving average ($5.90) and 52.33% below its 200-day moving average ($9.44). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is HCWB overbought or oversold?
At the July 15, 2026 close, HCWB's RSI(14) was 23.2, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, HCWB has $1.2M in cash with $6.6M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow is running at -$10.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has pulled back from $6.7M (2022) to $54K (2025), a 99% decline worth watching.
With a beta above 1.5, HCWB tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing HCWB.